Our laboratory reported that acquired resistance to cetuximab is accompanied by EGFR-dependent activation of HER3 in non-small cell lung cancer (NSCLC) and HNSCC [19, 30, 31]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.